Related Experiment Video
Updated: Jul 25, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Clinical and pharmacological effects of treatment with a new antidepressant
Abstract:
The novel tetracyclic piperazino-azepine compound Org GB 94 (Tolvon, Tolvin) in a dose of 20 mg three times daily was found to be of save markedly and significantly less side-effects. Patients with reactive depression and those with endogenous depression reponded equally well to Org GB 94. No correlation was found between plasma levels of Org GB 94 and either clinical effects or side-effects. Org GB 94 did not alter the tyramine pressor response, in contrast to amitriptyline.
More Related Videos
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
10:54Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
Published on: November 21, 2025
Related Concept Videos
The Placebo Effect
Clinical Trials: Overview
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications